COVID-19 - Pipeline Analysis - Drug Development Strategies by Therapy, RoA, Target, Mechanism of Action, and Therapeutic Modalities

PART 01: Executive Summary

PART 02: Scope

• 1.1 Scope of the report

PART 03: Disease overview

• 1.2 Introduction

PART 04: Regulatory framework

PART 05: Drug development landscape

• 1.3 Drugs under development

PART 06: Drug development strategies

• 1.4 Therapies employed
• 1.5 RoA
• 1.6 Therapeutic modalities
• 1.7 Targets for drug development
• 1.8 Mechanism of action (MoA)

PART 07: Recruitment strategies

• 1.9 Geographical coverage
• 1.10 Recruitment status
• 1.11 Gender of participants
• 1.12 Age structure
• 1.13 Recruitment volume

PART 08: Key companies

• 1.14 Overview
• 1.15 Type of players

PART 09: AbbVie Inc.

• 1.16 Overview

PART 10: AIM ImmunoTech Inc.

• 1.17 Overview

PART 11: Ansun BioPharma

• 1.18 Overview

PART 12: APEIRON Biologics AG

• 1.19 Overview

PART 13: Ascletis Pharma Inc.

• 1.20 Overview

PART 14: Blade Therapeutics Inc.

• 1.21 Overview

PART 15: Can-Fite BioPharma Ltd.

• 1.22 Overview

PART 16: CanSino Biologics Inc.

• 1.23 Overview

PART 17: Clover Biopharmaceuticals

• 1.24 Overview

PART 18: F. Hoffmann-La Roche Ltd.

• 1.25 Overview

PART 19: FUJIFILM Corp.

• 1.26 Overview

PART 20: Gilead Sciences Inc.

• 1.27 Overview

PART 21: IMV Inc.

• 1.28 Overview

PART 22: InflaRx GmbH

• 1.29 Overview

PART 23: Inovio Pharmaceuticals Inc.

• 1.30 Overview

PART 24: Johnson & Johnson Services Inc.

• 1.31 Overview

PART 25: Mallinckrodt Plc

• 1.32 Overview

PART 26: Moderna Inc.

• 1.33 Overview

PART 27: NeuroRx Inc.

• 1.34 Overview

PART 28: Novavax Inc.

• 1.35 Overview

PART 29: OncoImmune Inc.

• 1.36 Overview

PART 30: OyaGen Inc.

• 1.37 Overview

PART 31: Pulmotect Inc.

• 1.38 Overview

PART 32: RedHill Biopharma Ltd.

• 1.39 Overview

PART 33: Regeneron Pharmaceuticals Inc.

• 1.40 Overview

PART 34: Sanofi

• 1.41 Overview

PART 35: SLA Pharma AG

• 1.42 Overview

PART 36: Sorrento Therapeutics Inc.

• 1.43 Overview

PART 37: Swedish Orphan Biovitrum AB

• 1.44 Overview

PART 38: Symvivo Corp.

• 1.45 Overview

PART 39: Takeda Pharmaceutical Co. Ltd.

• 1.46 Overview

PART 40: Tonix Pharmaceuticals Holding Corp.

• 1.47 Overview

PART 41: Vanda Pharmaceuticals Inc.

• 1.48 Overview

PART 42: Vaxart Inc.

• 1.49 Overview

PART 43: Appendix

• 1.50 List of abbreviations